OSRH OSR Health, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1840425 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.4%
TTM net income YoY32.8%
TTM EPS YoY68.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin24.3%
Operating margin-946.7%
Net margin-599.0%
FCF margin—
EBITDA margin-944.8%
Returns
ROE-10.2%
ROA-5.6%
ROIC (approx.)-12.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets24.5%
Debt / equity0.00x
Current ratio0.15x
Interest coverage-34.95x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.91M | $3.53M |
| Cost of revenue | $2.31M | $2.72M |
| Gross profit | $592,905 | $811,236 |
| R&D expense | $318,446 | $161,155 |
| SG&A expense | $18.93M | $12.50M |
| Operating income | -$18.34M | -$11.69M |
| Interest expense | $506,196 | $51,335 |
| Pretax income | -$28.89M | -$11.89M |
| Income tax | -$1.83M | -$1.56M |
| Net income | -$18.01M | -$2.41M |
| EBITDA | -$18.33M | -$11.69M |
| EPS (basic) | -0.92 | -4.79 |
| EPS (diluted) | -0.80 | -4.79 |
| Weighted avg. shares (diluted) | 22.56M | 2.15M |
| Balance sheet | ||
| Cash & equivalents | $1.70M | $341,543 |
| Receivables | $319,304 | $904,456 |
| Inventory | $196,432 | $922,107 |
| Current assets | $2.82M | $2.33M |
| PP&E, net | $169,130 | $2,334 |
| Goodwill | $24.95M | $24.35M |
| Intangibles | $142.46M | $148.06M |
| Total assets | $171.24M | $175.24M |
| Current liabilities | $17.17M | $3.46M |
| Short-term debt | $0 | $1.80M |
| Long-term debt | $0 | $497,615 |
| Total debt | $0 | $2.30M |
| Total liabilities | $44.20M | $32.03M |
| Shareholders' equity | $77.64M | -$8.33M |
| Net debt | -$1.70M | $1.96M |
| Shares outstanding | 26.60M | 2.15M |
| Cash flow statement | ||
| Operating cash flow | -$4.33M | -$1.85M |
| Investing cash flow | -$2.64M | $503,611 |
| Financing cash flow | $8.37M | $1.18M |
| Depreciation & amortization | $7,269 | $5,900 |
| Share buybacks | — | $36.23M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.